11
Drug manufacture, procurement, wholesaling
distribution
2
Drug manufacture
2
33
Local medicine manufacture
Content
• Political side: different levels of local medicine manufacture may exist – the country should choose its best
• Regulatory side: regulation and control of local medicine manufacture
4
1. Political side
4
55
Local drug manufacture, 1
WHO: different levels may exist• a) most advanced: research and development
of new APIs Active Pharmaceutical Ingredients also manufacture of APIs + dosage-form production
isolation of herbal principles
• b) less advanced: manufacture of established APIs + intermediates, + their dosage-forms
66
Local drug manufacture, 2
(Different levels)• c) only finished products (every kind of dosage-
forms, including sterile) from purchased APIs and excipients
• d) only some simpler finished products (dosage forms simpledifficult: e.g.
solution/ointmenttabletssterilevaccines)
• e) the least advanced manufacture: only (re)packaging of purchased bulk finished products
7
To make the right choice…
…is a political issue! Principles:• Meeting the local needs should be the
first• Organising lower level, but working
manufacture is better than aiming higher level that can not operate
• But drug export, if possible, ensures profit and power…
7
8
Achieving this political will……needs various means depending on the
situation!• Is the pharma industry public or private?
– Public (Government owned/subsidized): direct interference and decision-making
– Private: only indirect measures (taxes, drug reimbursement system, etc.)
– PPP (public-private-partnership): in between
8
99
If public
• The regulation is easier – the state „orders”• Different levels
– Factories belong to Ministry of Health (MoH) or Ministry of Industry, under their supervision, ministerial decisions on what is produced
– State-owned industry (as a rule, organised into a Trust), the Sates specifies (kinds and quantities) of medicines to be provided
– Factories are individual profit-centers, the State only nominates management and receives part of the profit
1010
If private
• Fully domestic?• Bought/shared by multis? between these
two: „Domestic” but it is on the share-market
• How to regulate them?By legislation, taxation? Local management? More
direct ways?
Profit remains – repatrioted? (remains in the country or taken away by the foreign owner?)
1111
Which level does meet the local
needs? 1. API manufacture
Not an aim in itself! To decide:• are there chemical/biological
traditions, is expertise available?• study of international market for raw
materials for local API manufacture (are they available?)
• or better rely on API import?
1212
Established APIs manufactured
• What is the standard?• Does the country have its own
Pharmacopoeia? • Or regional or well-known (e.g. USP,
BP) Pharmacopoeias accepted or WHO International Pharmacopoeia?
• Is there a policy which quality to manufacture?
1313
„Is there a policy which quality to manufacture?”
• Certain manufacturers apply more than one standard
• After a batch is manufactured, the QC analyses will decide which standard (e.g. which Pharmacopoeia) has been met
• This is a wrong approach!This is a wrong approach!
1414
Which level does meet the local
needs? 2. Finished drug product manufacture
• Human resources + supporting infrastructure (water and energy supplies) available?
• Ingredients purchased - price vs. quality offered often products meeting the requirements of only outdated Pharmacopoeias offered
1515
Which level does meet the local
needs? 2. Finished drug product manufacture
• Complete self-reliance (i.e. local manufacture of every medicine needed) should not be an aim! No country in 100%.– Thus, local manufacture + import
• Aiming also export? But is there a market? Quality could be provided?
• But local medicine manufacture creates new jobs, decreases prices...
16
Right local manufacture and standards are extremely
important!
The sad mebendazole tablet story!
It happened a few years ago
16
17
• Mebendazol is an agent used to kill different worms (e.g. pinworms) that infected the human organism
• The infection rate is high in countries with limited hygienic conditions, e.g. soma parts of Africa
• UN organizations decided to finance free of charge mebendazole-medication to children in some African countries
17
18
• The WHO International Pharmaceopoeia had a monograph for mebendazole syrup only
• The decision was– To prefer tablet dosage-form (to avoid distributing
„water” to countryside)– Sucking tablet, for longer action– To find a local manufacturer (to avoid long-distance
distibution)
• Local producer was found. It was ready to develop mebendazole sucking tablets
18
19
• But it could produce only big tablets• Decision: for the tablets would disintegrate after the
mebendazole was dissolved and „sucked-out”, no problem
Until now, everything does seem to be logcal, does not?• However, mebendazol has various crystal
modifications! The metastabil modification can be dissolved from tablets, the stable form can not!
• The metastable form is manufactured, but, if moisture is present, it is transformed to the stable modification!
19
20
• This previous information was not taken into consideration/known by the decision-makers
• Locally manufactured sucking tablets were packed in a non-water-resistant material
• Mebendazole transformed to its stable crystal form, the tablets were sucked by children in vein. They got tired of sucking and swallowed the big tablet
• Six children suffocated and died before the issue was identified! 20
21
Thus,Everybody was benevolent, but
• The overall knowledge in the product was lacking
• The product development and control were not done according to international standards
• Six children were killed by a drug product distributed free of charge by UN bodies!
(end of the story)
21
2222
If mostly import
– done by the Government? Or– encouraged (or forced) by the Government?
• Bulk purchasing? (Cheaper!) – If API is imported, bulk purchasing may
ensure quality-safety-efficacy, but more acceptable price, then the API can be sold to private or „distributed” to public factories
– If finished products imported in bulk, a local re-packaging factory is needed
23
Even import of finished drug products…
• …needs some preparedness!
• It is very dangerous to buy drugs if you have no local quality control facilities:– Counterfeit (fake) products– Low-quality or adulterated APIs
• For countries that have no local control facilities the WHO offered a solution
23
2424
WHO Certification Scheme for products moving in international
commercefor medicinal products:• certified by the exporting authority to the
importing one, when the latter has limited possibilities to control:– it has been registered in the country of origin– it is subject of GMP inspection– possibility of attaching approved information
material
2525
WHO Certification Scheme for APIs
• info about API manufacturer• against brokers who
– sell everything by repackaging and relabelling as if it were newly produced
– providing no information on, e.g. potentially harmful solvent residues
• EU: either own manufacture or Drug Master File or European Pharmacopoeia Certificate of Suitability
2626
Most advanced (EU) requirements for data on API manufacture when submitting applications for medicinal product marketing authorisation
• The product manufacturer is also the API manufacturer: submits also API manufacture basic data
• The product manufacturer is different from the API manufacturer:– the latter has European Pharmacopoeia
Certificate of Suitability– the product manufacturer requests the API
manufacturer to send the basic API manufacturing data („Drug Master File”) to the authority where the marketing authorisation request for the medicinal product has been submitted
2727
European Pharmacopoeia (EP) Certificate of Suitability
The API manufacturer initiates it• by sending the synthesis route and basic data
together with normal impurity (intermediers + decomposition products) samples to the European Department of Quality of Medicines (EDQM)
• EDQM checks whether the EP monograph methods are suitable to detect/quantify impurities
• If yes, the Certificate (referred to as Certificat of European Pharmacopoeia, CEP) issued, specific to the given API (manufacturer, synthesis)
28
Purchase of drug (and excipient) substances only from reliable sources
• is extremely important!• As indicated by the „Glycerol story”• In the 1960s years, in Haiti, about 50
children died• Although the reason was identified,
still there are children deaths in the developing World, every year!
• Why?28
29
Glycerol is used as cheap sweetening agent in cough syrups for children
• The cheapest „drug quality” glycerol can be purchased from brokers (who buy it, re-labels and sells. Often „technical quality” glycerol is purchased and re-labeled as „pharmacopoeial”)
• However, diethylene glycol (toxic!) has the trade name „Glycol”
29
30
You already see, what happens
• Brokers, by mistake, purchase also GLYCOL, mix it to GLYCEROL and sell it as glycerol
• Poor country manufacturers do not have access to GLC analyses for every purchased batch, use them as purchased = toxic symptoms and deaths – in vein!
30
31
2. Professional side
3232
Regulation of local medicine manufacture
The three regulatory issues
• Is manufacturing authorisation needed? By whom? (MoH, Min.of Industry…)
• If so, are minimum standards issued (GMP)? (If yes: which GMP?)
• Inspected? By whom?
33
Manufacturing authorisation 1
• In the majority of the countries, drug manufacture needs prior authorisation
• By whom?– Ministry of Health– Drug Regulatory Authority (if independent
from the MoH)– Other Ministry (Industry)– ?
34
Manufacturing authorisation 2
If authorisation needed,• Are there exemptions? (E.g. drug compounding
in pharmacies, as a rule, not „manufacture”; local „herbalists other kinds of traditional medicine?)
• What does it cover? („General drug manufacturing authorisation” - this does not exist in most of the cases, or according to dosage-forms, or sterile – non-sterile, or which other principle?)
35
Manufacturing authorisation 3
If authorisation needed,• What are the prerequisites? In most of the
cases: Good Manufacturing Prcatices (GMP, see later)
• If so, which GMP?– ICH-based as in the developed World (ICH: see
later)
– the WHO GMP– local GMP?
36
ICH• International Conference on Harmonisation• Participants:
– USA, Japan, European Union– both Drug Regulatory Authority and Pharma Industry
• Development of common rules, guidelines, methodology, etc. for drug registration/authorisation
• Definitely and admittedly to meet the needs of the msot developed countries (e.g., in the guide for drug stability studies no „hot and humid” conditions, that do not apply in these ICH countries)
37
GMP, 1
• It is a quality assurance system dedicated to drug manufacture
• API chapter and Drug Product Chapter• Both: basic principles, personnel (incl.
hygiene), premises and equipment, documentation, production, quality control, contract production and analysis, complaint handling and recall, self-inspection parts + Annexes (e.g. sterile production, process validation, manufacture of medicinal gases, etc.)
38
GMP, 2• The ICH GMP and the WHO GMP differ
only• in the order of the chapters• the ICH one contains more annexes
– for the ICH one is intended for the most developed countries, the WHO one for less developed (e.g. no medicinal gas or radiomedicine manufacture expected
„Local” GMPs can be regional (such as ASEAN GMP) or national. As a rule, they follow WHO GMP, sometimes its less updated versions
39
Manufacturing authorisation, 4
• Are authorised manufacturers subjected to regular GMP inspections? (=on-the-spot visit and checking of personal and other – see GMP chapters – requirements)
• Inspectors are governmental officials, belonging to (MoH, Min. of Ind., DRA, etc.)
• Issues:– Where inspectors were trained in GMP?– Are there conditions (e.g. education, industrial
experience, regular training)?
40
Manufacture and drug compounding
• A crucial issue: are the industrial mdrug manufacture and large-scale drug compounding in bigger pharmacies (that also sell some compounded drugs to other pharmacies) separated?
• If so, how is the borderline set?
4141
Drug procurement
4242
Drug procurement
The total of activities resulting in the availibility of medicines in a country: purchasing and distribution
This term is used mostly in developing countries when the State is directly involved in the medicine supply for the interest of the inhabitants
4343
Drug procurement
• Public or private sector prevails the medicine supply? (If the latter, as a rule drug wholesalers or „importers” or others?)
• Public sector: the MoH itself or (semi)autonomous State Procurement Agencies?
• If public sector in the procurement: systematic tendering needed
4444
Procurement, important
• Import: WHO Certification Scheme (assurance of registration in the country of origin + GMP surveillance)
• Info on product inter-changeability („what can I buy instead of it, if not available”?)
4545
Interchangeability, substitution, etc.
• The correct information is crucial
• Used in various meanings
• It should always be clarified!
4646
Interchangeability, substitution, etc. 1
• Same API, same strength, similar dosage-form (e.g. tablets and capsules), bioequivalence proven
interchangeable, theoretically substitution without problems.
But: ready-made and reconstituted syrups…
4747
Interchangeability, substitution, etc. 2
• Same API, same strength, similar dosage-form (e.g. tablets and capsules), bioequivalence not known
is the liberation crucial (i.e. the rate-limiting step in the organism)? Individual action (e.g. pain-killer vs. steady-state – absorption in mouth or stomach or only from small intestine?
4848
Interchangeability, substitution, etc. 3
• Same API, different strength, similar dosage-form (e.g. tablets and capsules)…
e.g. double strength – can it be broken to two equal parts? Not for capsules…
4949
Interchangeability, substitution, etc. 4
• Different API, same therapeutic group…
e.g. ACE inhibitors – selectivity – patient’s reaction may be different…
5050
Interchangeability, substitution, etc. 5
• Different API, different therapeutic groups, similar therapeutic application…
e.g. antihypertensives: duiretics – ACE inhibitors – Ca-channel inhibitors – beta-blockers – alpha-blockers…
Questionable, but may be a must in some Third World countries
5151
Procurement, premises
• Warehouses needed to store the medicines (controlled temperature, cold rooms…)
• If central storage: distribution means (trucks, cars – more frequently to the countryside – suitable roads?)
• If regional storage: suitable regional warehouses
5252
Procurement, process• Estimates (quarterly/annually)But no “planned economy!” Lead-time• Based on health status, morbidity, past
period, etc.• Buying Public: aggregation of national needs
• large quantitites but climate, warehousing, shelf-life
• in bulk and re-package but stability, liability
5353
If possible, avoid brokers!
Broker: (mostly international) company purchasing cheap medicines (mostly APIs, sometimes also products) „on the world market” (the manufacturer, as a rule, not known), analyses until a Pharmacopoeia found that the delivery complies with, then re-packaging, re-labeling and offered for sale as „newly manufactured” according to this Pharmacopoeia
5454
Special procurement: donations
• WHO guidelines: >6 months to expiry date, known and needed by the recipient country
• Regulatory authority and pharmaceutical expertise involved
• Otherwise: only export of environmental/waste problems from donor countries
5555
Donations• Info: what are the drugs that are
really needed in the acceptor country vs. drugs that not needed in donor country…
• Not those collected back from patients
or to be wasted!
5656
Distribution, drug wholesaling
5757
Distribution/Wholesaling
• Only authorised wholesalers? By whom? GMP? Inspections?
• Storage conditions also during transport
• Interim storage (airport, freeports), even cold chains for vaccines
5858
Storage conditions also during transport
• „TempTags” in the deliveries (devices registering temperature) – the requirement is contained in the contract with transport companies?
• Is it specified who will be in charge of checking TempTags?
5959
Standard for drug manufacture
Also for drug wholesaling (some parts)
Good Manufacturing Practice (GMP)
• General Principles
• Special Annexes (sterile production, medicinal gases, clinical trial samples, etc.)
6060
Our recent special probleme: counterfeit drugs
• = intentional falsification for profit
• WHO: up to 50% in some Third World countries!
6161
Counterfeit drugs, types 1
• Good quality, mislabelled using a manufacturer’s name and brand, well-known in the region
• The same with bad quality: ingredients with more impurities, less stable, API outside (mostly below) the limits
6262
One is genuine, one is counterfeit!
6363
Counterfeit drugs, types 2
• Bad quality: much less API 50% to 10% (some API contained to be identified by spot tests or basic tests)
• No API at all! Life-threatening e.g. antibiotics, vaccines, antimalaria medicines
6464
Counterfeit drugs, types 3
Interesting to note:
• developing countries: basic (mostly life-saving!) drugs
• developed countries: life-style drugs (e.g. sildenafil)
counterfeited!
6565
Counterfeit drugs and the supply chain, 1
Different vulnerability!
• Drugs pharmacy-only, pharmacy owned by pharmacists, mostly drugs sold in pharmacies, drugs bought from licensed wholesalers
6666
Counterfeit drugs and the supply chain, 2
• Drugs pharmacy-only, pharmacy owned by pharmacists, not only drugs sold in pharmacies, products bought from different sources
• Drugs pharmacy-only, pharmacy owned by laymen/chains, not only drugs sold in pharmacies, products bought from different sources
6767
Counterfeit drugs and the supply chain, 3
• Drugs sold in ordinary shops, fuel-stations, even markets
• Distant and Internet-selling…
68
Complexity of the supply chain
Earlier:
manufacturer
wholesale distributor
pharmacy
69
Complexity of the supply chain
API manufacturer
international transport Co
product manufacturer
broker
wholesaler
international transport Co
global wholesaler
distributors
central warehous
70
Exam topic!
71
Drug manufacture, procurement and wholesale distribution
• Manufacture– Discuss the different levels of local manufacture. Self-reliance?Export?– State-owned or public factories versus regulation of the private pharma
industry– Is authorisation needed? By whom? GMP and inspection– Importance of WHO Certification Scheme
• Procurement– Definition– Possibilities of private or public procurement– Semi-autonomous Procurment Agencies, tendering– The interchangeability issue– How to make procurement estimates?– WHO rules on donations
• Wholesale distribution– Authorisation?– Storage and transport– Final and interim storage– The counterfeit issue